CER Daily Newsfeed

Apixaban Safer than Rivaroxaban for Thrombosis Treatment, Study Finds

(3/20, Corrinne Burns, The Pharmaceutical Journal) reports “The anticoagulant apixaban (Eliquis; Bristol Myers Squibb and Pfizer) is safer than rivaroxaban (Xarelto; Bayer) for the treatment of venous thrombosis, study results have revealed. Publishing the findings of the study in the New England Journal of Medicine on 12 March 2026, researchers in Canada compared the rates of clinically relevant bleeding during a three-month period of patients taking either direct oral anticoagulant (DOAC) and found that apixaban has a reduced risk of bleeding events.” Subscription Required

Real-World Study Suggests CKM Therapies May Benefit Patients With T1D and CKD

(3/19, The American Journal of Managed Care) reports “A new real-world analysis suggests that cardio-kidney-metabolic (CKM) therapies, widely used in type 2 diabetes (T2D), may offer meaningful kidney benefits for patients with type 1 diabetes (T1D) and chronic kidney disease (CKD) without increasing key safety risks. The findings, published in Diabetes, Obesity and Metabolism, provide early evidence supporting the potential role of these therapies in a population that has historically lacked targeted treatment options.” Full

The FDA Doesn’t Have a GLP-1 Problem. It Has an Evidence Problem.

(3/20, Moe Alsumidaie, The Clinical Trial Vanguard) comments “...The Prescription Drug User Fee Act VII commitments include explicit language about advancing RWE standards for regulatory decision-making. What does not yet exist is a documented, division-specific standard for when trial emulation evidence is sufficient for a primary label expansion — not a supplemental claim, not an accelerated approval placeholder, but a full indication based on observational data that was designed with randomized-trial discipline from the outset. If the FDA continues to treat that question as unanswerable, sponsors will continue designing expensive, underpowered trials to generate regulatory cover rather than scientific insight.” Full

Video: Patti's People - Patti Peeples Speaks with Michael Drummond Part 1

(3/20, The Evidence Base) “In this ‘Patti’s People’ episode, Patti Peeples of the The Peeples Collaborative speaks with Michael Drummond, Professor Emeritus and former Director, Centre for Health Economics, University of York, where they discuss topics including the evolving role of health economists in policy, the ongoing debate about ‘Value’ in healthcare, and budget constraints and opportunity cost in health systems.” View Video

U.K. to Take Another Look at Cost-Effectiveness of Alzheimer’s Drugs

(3/20, Andrew Joseph, STAT+) reports “U.K. health officials on Friday said they had reopened a review of two new Alzheimer’s therapies after previously finding they did not provide good therapeutic value for how much they cost...‘NICE was right to look again at the evidence in front of them and it’s welcome that our appeal has been upheld,’ Chris Stokes, Lilly’s general manager for Northern Europe, said...‘This news offers a welcome glimmer of hope for the Alzheimer’s disease community in England,’ Eisai said in a statement.” Subscription Required